Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVAnT1A: COVID-19 Vaccine for Type 1 Diabetes Prevention
NCT06452654Phase 4Recruiting
- Sponsor
- Technical University of Munich
- Start
- May 2024
- Primary completion
- Oct 2027
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 5
01
Overview
A Phase 4 trial of tozinameran in type 1 diabetes mellitus (T1D), sponsored by Technical University of Munich. Started May 2024; status: recruiting.
02
Drugs
tozinameran
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06452654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06452654.